Randomised, controlled trial on fluid restriction in pulmonary arterial hypertension, Respiration, September 9, 2026

A prospective, randomised, controlled single-centre study looking at whether fluid restriction (FR) helps pulmonary arterial hypertension patients with right heart failure and signs of volume overload. 41 patients (average age 70, mostly World Health Organisation (WHO) Functional class III, were split between intensified fluid restriction counselling (around 1.5 litres per day) and routine fluid restriction […]

Randomised, controlled trial on fluid restriction in pulmonary arterial hypertension, Respiration, September 9, 2026 Read Post »

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026

The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) were presented today at the ERS Congress! The Alliance for Pulmonary Hypertension Vice President Louise Bouman – van der Waal was at the congress and attended this important session. Here is the link to the article: https://lnkd.in/evX7wHhe Pisana Ferrari, President of

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026 Read Post »

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026

Some patients with pulmonary arterial hypertension experience difficulties with memory, thinking, or mood. A group of Chinese researchers have investigated whether reduced blood flow to the brain is connected to heart strain and disease severity. They compared brain scans from 30 people with pulmonary arterial hypertension and 51 healthy individuals matched for age and sex.

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026 Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026

The findings of a multi-center randomized controlled trial investigating the long-term efficiency of rehabilitation in patients with pulmonary arterial hypertension was published in the Annals of the American Thoracic Society on July 20, 2026. The study followed 47 patients with stable pulmonary arterial hypertension across 9 French centers, looking at the long-term impact of a

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026 Read Post »

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026

In a recent LinkedIn post Prof. Werner Seeger writes that the GoDeep meta-registry analysis about the predictive power of pulmonary artery stiffness – right ventricular interplay in mild pulmonary hypertension (PH) is now online. He reports that in the analysis, notably, parameters integrating pulsatile vascular load and interdependent right ventricular function possess predictive power independent

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026 Read Post »

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026

A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same disturbance shows up in other

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026 Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the French FONCE-HTAP randomized controlled trial, Annals of American Thoracic Society, July 20, 2026

A French multicenter trial (9 centers, 2015–2022) tested whether a 3-month supervised rehabilitation program improves 12-month exercise capacity in pulmonary arterial hypertension patients, using a Zelen design to limit performance bias — addressing a gap left by prior short-term, open-label studies. Key findings: Conclusion: A 3-month supervised rehabilitation program produced a durable, significant improvement in

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the French FONCE-HTAP randomized controlled trial, Annals of American Thoracic Society, July 20, 2026 Read Post »

Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review via the Pulmonary Vascular Research Institute (PVRI), Pulmonary Circulation, July 14, 2026

A review recently published in Pulmonary Circulation brings together academic and industry researchers (via the PVRI Innovative Drug Discovery Initiative) to consolidate current knowledge on activin signaling inhibitors (ASIs), the role of specific Bone morphogenetic protein (BMP) ligands, efficacy/safety data, and considerations for developing next-generation activin signaling inhibitors. Key points: Open questions remain about: the

Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review via the Pulmonary Vascular Research Institute (PVRI), Pulmonary Circulation, July 14, 2026 Read Post »

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026

In pulmonary arterial hypertension there are significant disparities in epidemiology, clinical outcomes, and healthcare access that disproportionately affect historically neglected populations, including Black Americans, Hispanic Americans, and American Indians. A State-of-the-Art review recently published on CHEST examines the disparities in the three groups. Key points: Conclusion: These disparities stem from structural/socioeconomic barriers and discrimination—not biological differences.

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026 Read Post »

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026

In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026 Read Post »

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026

Over the past 40 years, treatment for pulmonary arterial hypertension (PAH) has changed dramatically. What was once considered a disease with very few treatment options is now managed with a growing range of therapies that help people live longer and enjoy a better quality of life. A review recently published in Circulation looks back at

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026 Read Post »

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026

Researchers at the Suqian First Hospital in Suqian, Chian, China tested whether adding mindfulness-based stress reduction (MBSR) to standard cardiopulmonary rehabilitation could benefit pulmonary arterial hypertension patients more than usual care alone. Fifty stable patients were split into two groups: one did a 6-week combined mindfulness-based stress reduction and rehab program, the other received standard

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026 Read Post »

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026

This “How I Do It” article addresses a practical question now facing pulmonary arterial hypertension (PAH) clinicians: as sotatercept gets added to background combination treatment, some patients on prostacyclin therapy show sustained improvement — raising the question of whether their prostacyclin dose can be safely reduced. The challenge is that standard monitoring tools (functional class,

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026 Read Post »

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026

This single-center retrospective study, conducted at Qilu Hospital, Shandong University (China), from February 2022 to November 2023, set out to compare two strategies for selexipag-based triple combination therapy in patients with pulmonary arterial hypertension (PAH): starting all three drugs together (initial/upfront triple therapy) versus adding selexipag on top of existing dual therapy (early sequential triple

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026 Read Post »

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026

French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program. They found that both treatments lowered the resistance in the blood vessels of the lungs, making it easier for blood to flow. However, the treatments worked

Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026 Read Post »

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026

Researchers from China have traced the remarkable 30-year evolution of pulmonary arterial hypertension treatment, from a disease with no effective options to one on the cusp of a potential cure. What was once described as the “cancer of cardiovascular diseases” — with a median survival of just 2.8 years after diagnosis — has become a

Thirty Years of Progress in Pulmonary Arterial Hypertension Treatment: From Despair to Hope, Chinese Medical Journal, May 19, 2026 Read Post »

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026

A 10-week fully remote, home-based exercise programme for people with pulmonary hypertension (pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) was found to be both acceptable and beneficial, according to a study conducted by a group of Irish researchers, based on qualitative interviews with 13 participants. The programme combined aerobic, resistance and respiratory

Flexible, Accessible, Effective: Patient Perceptions of the Pulmonary Hypertension and Home-Based (PHAHB) Physical Activity Intervention, Pulmonary Circulation, April 29, 2026 Read Post »

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial

This article is not new (it dates back to 2010) but we are publishing it because pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are often confused, whereas they are very different conditions with different diagnostic approaches and treatments. Mixing them up can lead to serious diagnostic and therapeutic errors. Key points: *Pulmonary hypertension is

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial Read Post »

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026

Researchers from Canada have published a review which summarizes recently established and emerging signalling pathways that may influence the next generation of targeted pulmonary arterial hypertension therapies. They note that the therapeutic landscape for this condition is moving towards mechanism-based approaches with the potential to alter the course of the disease. In particular, the transforming

Scientific review of current and emerging signalling pathways in pulmonary arterial hypertension, Current Opinions in Pulmonary Medicine, May 5, 2026 Read Post »

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026

Assessment of exercise provides important prognostic information about pulmonary arterial hypertension patients. Researchers from the UK have recently published a review of current digital alternatives to traditional outcome measures. The 6-minute walk test (6MWT) is a key tool for monitoring pulmonary arterial hypertension, but since care is often centralized, patients may only do it once

Remote exercise assessment in pulmonary hypertension, Current Opinions in Pulmonary Medicine, May 7, 2026 Read Post »

TRANSLATE »
Scroll to Top